These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

793 related articles for article (PubMed ID: 28778958)

  • 1. Cell-Free DNA in Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis.
    Spindler KG; Boysen AK; Pallisgård N; Johansen JS; Tabernero J; Sørensen MM; Jensen BV; Hansen TF; Sefrioui D; Andersen RF; Brandslund I; Jakobsen A
    Oncologist; 2017 Sep; 22(9):1049-1055. PubMed ID: 28778958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methodological, biological and clinical aspects of circulating free DNA in metastatic colorectal cancer.
    Spindler KG
    Acta Oncol; 2017 Jan; 56(1):7-16. PubMed ID: 28010185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating free DNA as biomarker and source for mutation detection in metastatic colorectal cancer.
    Spindler KL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
    PLoS One; 2015; 10(4):e0108247. PubMed ID: 25875772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Total circulating cell-free DNA as a prognostic biomarker in metastatic colorectal cancer before first-line oxaliplatin-based chemotherapy.
    Hamfjord J; Guren TK; Dajani O; Johansen JS; Glimelius B; Sorbye H; Pfeiffer P; Lingjærde OC; Tveit KM; Kure EH; Pallisgaard N; Spindler KG
    Ann Oncol; 2019 Jul; 30(7):1088-1095. PubMed ID: 31046124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cell-free DNA in healthy individuals, noncancerous disease and strong prognostic value in colorectal cancer.
    Spindler KL; Appelt AL; Pallisgaard N; Andersen RF; Brandslund I; Jakobsen A
    Int J Cancer; 2014 Dec; 135(12):2984-91. PubMed ID: 24798213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical utility of KRAS status in circulating plasma DNA compared to archival tumour tissue from patients with metastatic colorectal cancer treated with anti-epidermal growth factor receptor therapy.
    Spindler KL; Pallisgaard N; Appelt AL; Andersen RF; Schou JV; Nielsen D; Pfeiffer P; Yilmaz M; Johansen JS; Hoegdall EV; Jakobsen A; Jensen BV
    Eur J Cancer; 2015 Nov; 51(17):2678-85. PubMed ID: 26508156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
    Karachaliou N; Mayo-de las Casas C; Queralt C; de Aguirre I; Melloni B; Cardenal F; Garcia-Gomez R; Massuti B; Sánchez JM; Porta R; Ponce-Aix S; Moran T; Carcereny E; Felip E; Bover I; Insa A; Reguart N; Isla D; Vergnenegre A; de Marinis F; Gervais R; Corre R; Paz-Ares L; Morales-Espinosa D; Viteri S; Drozdowskyj A; Jordana-Ariza N; Ramirez-Serrano JL; Molina-Vila MA; Rosell R;
    JAMA Oncol; 2015 May; 1(2):149-57. PubMed ID: 26181014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and clinicopathological significance of circulating tumor cells detected by RT-PCR in non-metastatic colorectal cancer: a meta-analysis and systematic review.
    Yang C; Zou K; Zheng L; Xiong B
    BMC Cancer; 2017 Nov; 17(1):725. PubMed ID: 29115932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan.
    Spindler KL; Pallisgaard N; Vogelius I; Jakobsen A
    Clin Cancer Res; 2012 Feb; 18(4):1177-85. PubMed ID: 22228631
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in mutational status during third-line treatment for metastatic colorectal cancer--results of consecutive measurement of cell free DNA, KRAS and BRAF in the plasma.
    Spindler KL; Pallisgaard N; Andersen RF; Jakobsen A
    Int J Cancer; 2014 Nov; 135(9):2215-22. PubMed ID: 24659028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Detection of tumor-derived cell-free DNA from colorectal cancer peritoneal metastases in plasma and peritoneal fluid.
    Van't Erve I; Rovers KP; Constantinides A; Bolhuis K; Wassenaar EC; Lurvink RJ; Huysentruyt CJ; Snaebjornsson P; Boerma D; van den Broek D; Buffart TE; Lahaye MJ; Aalbers AG; Kok NF; Meijer GA; Punt CJ; Kranenburg O; de Hingh IH; Fijneman RJ
    J Pathol Clin Res; 2021 May; 7(3):203-208. PubMed ID: 33635598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating free DNA integrity and concentration as independent prognostic markers in metastatic breast cancer.
    Cheng J; Holland-Letz T; Wallwiener M; Surowy H; Cuk K; Schott S; Trumpp A; Pantel K; Sohn C; Schneeweiss A; Burwinkel B
    Breast Cancer Res Treat; 2018 May; 169(1):69-82. PubMed ID: 29340881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Total cell-free DNA, carcinoembryonic antigen, and C-reactive protein for assessment of prognosis in patients with metastatic colorectal cancer.
    Spindler KG; Demuth C; Sorensen BS; Johansen JS; Nielsen D; Pallisgaard N; Hoegdall E; Pfeiffer P; Vittrup Jensen B
    Tumour Biol; 2018 Nov; 40(11):1010428318811207. PubMed ID: 30486767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ultra-Sensitive Mutation Detection and Genome-Wide DNA Copy Number Reconstruction by Error-Corrected Circulating Tumor DNA Sequencing.
    Mansukhani S; Barber LJ; Kleftogiannis D; Moorcraft SY; Davidson M; Woolston A; Proszek PZ; Griffiths B; Fenwick K; Herman B; Matthews N; O'Leary B; Hulkki S; Gonzalez De Castro D; Patel A; Wotherspoon A; Okachi A; Rana I; Begum R; Davies MN; Powles T; von Loga K; Hubank M; Turner N; Watkins D; Chau I; Cunningham D; Lise S; Starling N; Gerlinger M
    Clin Chem; 2018 Nov; 64(11):1626-1635. PubMed ID: 30150316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.
    Ørntoft MW; Jensen SØ; Øgaard N; Henriksen TV; Ferm L; Christensen IJ; Reinert T; Larsen OH; Nielsen HJ; Andersen CL
    Int J Cancer; 2021 Apr; 148(7):1665-1675. PubMed ID: 33320961
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monitoring levels of circulating cell-free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatment.
    Pastor B; André T; Henriques J; Trouilloud I; Tournigand C; Jary M; Mazard T; Louvet C; Azan S; Bauer A; Roch B; Sanchez C; Vernerey D; Thierry AR; Adenis A
    Mol Oncol; 2021 Sep; 15(9):2401-2411. PubMed ID: 33934494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment monitoring in metastatic colorectal cancer patients by quantification and KRAS genotyping of circulating cell-free DNA.
    Berger AW; Schwerdel D; Welz H; Marienfeld R; Schmidt SA; Kleger A; Ettrich TJ; Seufferlein T
    PLoS One; 2017; 12(3):e0174308. PubMed ID: 28328955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-Free DNA as a Diagnostic Blood-Based Biomarker for Colorectal Cancer: A Systematic Review.
    Petit J; Carroll G; Gould T; Pockney P; Dun M; Scott RJ
    J Surg Res; 2019 Apr; 236():184-197. PubMed ID: 30694754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circulating tumor DNA is effective for detection of KRAS mutation in colorectal cancer: a meta-analysis.
    Tang M; Deng Z; Li B; Peng Y; Song M; Liu J
    Int J Biol Markers; 2017 Oct; 32(4):e421-e427. PubMed ID: 28885658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating cell-free DNA in plasma of colorectal cancer patients - A potential biomarker for tumor burden.
    Bhangu JS; Taghizadeh H; Braunschmid T; Bachleitner-Hofmann T; Mannhalter C
    Surg Oncol; 2017 Dec; 26(4):395-401. PubMed ID: 29113658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.